Rojas MKJ, Yglesias DII, Hernández CVI

Language: Spanish
References: 15
Page:
PDF size: 268.32 Kb.

ABSTRACT

The following review offers a general approach from the dermatologic and rheumatologic point of view to the Juvenile Dermatomyositis disease (DMJ). DMJ is a systemic autoimmune disease, characterized by myositis of proximal muscles along with characteristic skin lesions. It usually appears at a very young age and affects more females than males. Its etiology has been associated with specific genetic and environmental factors. Besides skin and lungs, other affected organs include lungs, heart and vessels, and gastrointestinal tract. Currently, diagnosis is based on clinical manifestations, magnetic resonance and specific autoantibodies. Calcinosis is one of the most frequent and devastating complications of the disease. Treatment focuses on prompt start of corticosteroids at high doses. Disease-modifying drugs are used along with corticosteroids in more severe cases. Nowadays, prognosis of DMJ shows a decline in mortality since the establishment of the corticosteroid era.

REFERENCES

1. Kobayashi I, Akioka S, Kobayashi N, Iwata N, Takezaki S, Nakaseko H, et al. Clinical practice guidance for juvenile dermatomyositis (JDM) 2018-Update. Mod Rheumatol. 2020 Mayo 3;30(3):411–23.

2. Hutchinson C, Feldman B. Juvenile dermatomyositis and polymyositis: Epidemiology, pathogenesis, and clinical manifestations. In: Li S, Patterson M, editors. UpToDate; 2021.

3. Wu JQ, Lu MP, Reed AM. Juvenile dermatomyositis: advances in clinicalpresentation, myositis-specific antibodies and treatment. World Journal of Pediatrics. 2020 Febrero 26;16(1):31–43.

4. Swafford C, Roach ES. Juvenile Dermatomyositis and the Inflammatory Myopathies. Semin Neurol. 2020 Junio 6;40(03):342–8.

5. Dugan E, Huber A, Miller F, Rider L. File:Dermatomyositis2.jpg. Wikimedia Commons. 2020.

6. Hutchinson C, Feldman B. Juvenile dermatomyositis and other idiopathic inflammatory myopathies. In: Li S, Patterson M, TePas E, editors. UpToDate; 2022.

7. Leclair V, Lundberg IE. New Myositis Classification Criteria—What We Have Learned Since Bohan and Peter. Curr Rheumatol Rep. 2018 Abril 17;20(4):18.

8. Li D, Tansley SL. Juvenile Dermatomyositis—Clinical Phenotypes. Curr Rheumatol Rep. 2019 Diciembre 11;21(12):74.

9. Kwiatkowska D, Reich A. The Significance of Autoantibodies in Juvenile Dermatomyositis. Biomed Res Int. 2021 Noviembre 19;2021:1–6.

10. DeWane ME, Waldman R, Lu J. Dermatomyositis: Clinical features and pathogenesis. J Am Acad Dermatol. 2020 Febrero;82(2):267–81.

11. Kul Cinar O, Papadopoulou C, Pilkington CA. Treatment of Calcinosis in Juvenile Dermatomyositis. Curr Rheumatol Rep. 2021 Febrero 8;23(2):13.

12. Elahmar H, Feldman BM, Johnson SR. Management of Calcinosis Cutis in Rheumatic Diseases. J Rheumatol. 2022 Septiembre;49(9):980–9.

13. Poddighe D, Dauyey K. Macrophage activation syndrome in juvenile dermatomyositis: a systematic review. Rheumatol Int. 2020 Mayo 16;40(5):695–702.

14. Bellutti Enders F, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017 Febrero;76(2):329–40.

15. McCann LJ, Livermore P, Wilkinson MGL, Wedderburn LR. Juvenile dermatomyositis. Where are we now? Vol. 40, Clinical and Experimental Rheumatology. 2022.